Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme Files for Expanded Campath Label | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Genzyme Files for Expanded Campath Label

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme Corp. and Bayer HealthCare have submitted a sBLA to the FDA to expand the current product label for Campath to include first-line treatment of B-cell chronic lymphocytic leukemia (B-CLL). Campath is currently approved for the treatment of B-CLL patients who have been previously treated with an alkylating agent and have failed fludarabine therapy. Genzyme also plans to make a similar filing in Europe to support this label expansion.

The product is marketed outside the U.S. as MabCampath, by Bayer Schering Pharma AG, Germany and in the U.S. by Bayer HealthCare Pharmaceuticals, as Campath. The Phase III study was an international, randomized, controlled trial to satisfy a post-approval commitment to the FDA to show clinical benefit of Campath in B-CLL, and to complete the conversion to regular approval. Genzyme’s confirmatory study was completed in accordance with FDA timelines.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters